Nektar Therapeutics (NKTR)
Largest Insider Buys in Sector
NKTR Stock Price History Chart
NKTR Stock Performance
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Insider Activity of Nektar Therapeutics
Over the last 12 months, insiders at Nektar Therapeutics have bought $0 and sold $253,716 worth of Nektar Therapeutics stock.
On average, over the past 5 years, insiders at Nektar Therapeutics have bought $259,200 and sold $7.23M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,000 shares for transaction amount of $259,200 was made by Doberstein Stephen K (SVP & Chief Scientific Officer) on 2019‑09‑05.
List of Insider Buy and Sell Transactions, Nektar Therapeutics
| 2024-06-14 | Sale | CHESS ROBERT | director | 19,500 0.0101% | $1.20 | $23,400 | -1.71% | |
| 2024-05-17 | Sale | ROBIN HOWARD W | President & CEO | 16,650 0.0087% | $1.75 | $29,138 | -27.84% | |
| 2024-05-17 | Sale | Zalevsky Jonathan | Chief R&D Officer | 7,355 0.0039% | $1.75 | $12,871 | -27.84% | |
| 2024-05-17 | Sale | Wilson Mark Andrew | Chief Legal Officer | 6,260 0.0033% | $1.75 | $10,955 | -27.84% | |
| 2024-05-10 | Sale | Deep Track Capital, LP | 10 percent owner | 56,000 0.0308% | $1.78 | $99,630 | -21.14% | |
| 2024-02-20 | Sale | ROBIN HOWARD W | President & CEO | 20,033 0.0107% | $0.68 | $13,622 | +89.87% | |
| 2024-02-20 | Sale | Zalevsky Jonathan | Chief R&D Officer | 9,014 0.0048% | $0.68 | $6,130 | +89.87% | |
| 2024-02-20 | Sale | Wilson Mark Andrew | Chief Legal Officer | 7,606 0.0041% | $0.68 | $5,172 | +89.87% | |
| 2023-11-17 | Sale | ROBIN HOWARD W | President & CEO | 19,877 0.0105% | $0.49 | $9,740 | +79.08% | |
| 2023-11-17 | Sale | Zalevsky Jonathan | Chief R&D Officer | 9,646 0.0051% | $0.49 | $4,727 | +79.08% | |
| 2023-11-17 | Sale | Wilson Mark Andrew | Chief Legal Officer | 7,179 0.0038% | $0.49 | $3,518 | +79.08% | |
| 2023-09-18 | Sale | Ajer Jeffrey Robert | director | 4,359 0.0023% | $0.69 | $3,008 | -3.12% | |
| 2023-09-18 | Sale | Curet Myriam | director | 4,359 0.0023% | $0.69 | $3,008 | -3.12% | |
| 2023-08-16 | Sale | ROBIN HOWARD W | President & CEO | 19,998 0.0107% | $0.78 | $15,598 | -13.94% | |
| 2023-08-16 | Sale | Zalevsky Jonathan | Chief R&D Officer | 9,703 0.0052% | $0.78 | $7,568 | -13.94% | |
| 2023-08-16 | Sale | Wilson Mark Andrew | Chief Legal Officer | 7,221 0.0039% | $0.78 | $5,632 | -13.94% | |
| 2023-06-14 | Sale | WHITFIELD ROY A | director | 30,000 0.0164% | $0.57 | $17,100 | +8.29% | |
| 2023-05-16 | Sale | ROBIN HOWARD W | President & CEO | 20,361 0.0109% | $0.72 | $14,660 | -19.06% | |
| 2023-05-16 | Sale | Zalevsky Jonathan | Chief R&D Officer | 9,791 0.0052% | $0.72 | $7,050 | -19.06% | |
| 2023-05-16 | Sale | Wilson Mark Andrew | Chief Legal Officer | 7,543 0.004% | $0.72 | $5,431 | -19.06% |
Insider Historical Profitability
| Deep Track Capital, LP | 10 percent owner | 18344000 9.99% | $1.09 | 0 | 1 | |
| ROBIN HOWARD W | President & CEO | 863239 0.4717% | $1.09 | 1 | 75 | <0.0001% |
| CHESS ROBERT | director | 255273 0.144% | $1.09 | 0 | 44 | |
| Zalevsky Jonathan | Chief R&D Officer | 257670 0.1436% | $1.09 | 0 | 21 | |
| Wilson Mark Andrew | Chief Legal Officer | 230414 0.1278% | $1.09 | 0 | 18 | |
| Ajer Jeffrey Robert | director | 34153 0.0179% | $1.09 | 0 | 7 | |
| Curet Myriam | director | 27418 0.0144% | $1.09 | 0 | 3 | |
| HARRIS J MILTON | President of Nektar AL | 711416 0.3729% | $1.09 | 0 | 17 | |
| PATTON JOHN STUART | Chief Scientific Officer | 313880 0.1645% | $1.09 | 0 | 11 | |
| Thomsen Jillian B. | Chief Financial Officer | 313497 0.1643% | $1.09 | 0 | 43 | |
| Labrucherie Gil M | SVP, COO & CFO | 312905 0.164% | $1.09 | 0 | 58 | |
| NORTHCOTT JOHN | SVP & Chief Commercial Officer | 223210 0.117% | $1.09 | 0 | 6 | |
| WHITFIELD ROY A | director | 216250 0.1134% | $1.09 | 3 | 2 | +51.06% |
| GREER R SCOTT | director | 176574 0.0926% | $1.09 | 1 | 5 | +42.48% |
| Nicholson John | SVP & Chief Operating Officer | 162759 0.0853% | $1.09 | 0 | 22 | |
| Doberstein Stephen K | SVP & Chief Scientific Officer | 107668 0.0564% | $1.09 | 1 | 20 | +17.27% |
| Hora Maninder | SVP Pharma Dev & Mfg Ops | 94694 0.0496% | $1.09 | 0 | 18 | |
| GILL AJIT | Former Director, Pres. & CEO | 87991 0.0461% | $1.09 | 0 | 7 | |
| WINGER DENNIS L | director | 42750 0.0224% | $1.09 | 1 | 4 | +8.33% |
| Gergel Ivan P. | SVP & Chief Medical Officer | 41575 0.0218% | $1.09 | 0 | 12 | |
| KUEBLER CHRISTOPHER A | director | 40500 0.0212% | $1.09 | 0 | 10 | |
| Lingnau Lutz | director | 26700 0.014% | $1.09 | 0 | 14 | |
| WANG SUSAN | director | 20000 0.0105% | $1.09 | 0 | 4 | |
| BANSAL AJAY | Former CFO | 5166 0.0027% | $1.09 | 0 | 6 | |
| DRAPEAU LOUIS | Sr. VP Finance, CFO | 5000 0.0026% | $1.09 | 5 | 0 | <0.0001% |
Institutional Investor Ownership
| Deep Track Capital Lp | $17.19M | 10.02 | 18.4M | 0% | +$0 | 0.08 | |
| The Vanguard Group | $11.26M | 6.56 | 12.05M | +0.05% | +$5,852.76 | <0.0001 | |
| Acadian Asset Management | $7.07M | 4.12 | 7.57M | -3.19% | -$233,274.43 | 0.03 | |
| PRIMECAP Management Co | $6.51M | 3.79 | 6.97M | -0.5% | -$32,790.42 | 0.01 | |
| BlackRock | $5.49M | 3.2 | 5.88M | -3.7% | -$211,058.19 | <0.0001 | |
| Monaco Asset Management Sam | $5.45M | 3.18 | 5.83M | -2.37% | -$132,490.11 | 2.51 | |
| Renaissance Technologies | $4.32M | 2.52 | 4.62M | -13.23% | -$658,473.44 | 0.01 | |
| Tcg Crossover Management Llc | $3.74M | 2.18 | 4M | New | +$3.74M | 0.01 | |
| Stonepine Capital Management Llc | $3.25M | 1.9 | 3.48M | New | +$3.25M | 2.63 | |
| Citadel Advisors LLC | $2.98M | 1.74 | 3.19M | -43.22% | -$2.27M | <0.01 | |
| Millennium Management LLC | $2.79M | 1.63 | 2.98M | +86.98% | +$1.3M | <0.01 | |
| D. E. Shaw & Co. | $2.38M | 1.39 | 2.55M | -37.81% | -$1.45M | <0.01 | |
| Nantahala Capital Management Llc | $2.31M | 1.35 | 2.48M | New | +$2.31M | 0.24 | |
| Two Sigma Advisers LP | $2.09M | 1.22 | 2.24M | -27.01% | -$774,638.46 | <0.01 | |
| Two Sigma | $1.94M | 1.13 | 2.08M | -4.37% | -$88,787.29 | <0.01 | |
| Shay Capital Llc | $1.94M | 1.13 | 2.08M | New | +$1.94M | 0.58 | |
| Lynx1 Capital Management Lp | $1.93M | 1.13 | 2.07M | +7.24% | +$130,455.41 | 0.1 | |
| Geode Capital Management | $1.92M | 1.12 | 2.05M | +0.66% | +$12,587.61 | <0.0001 | |
| Gsa Capital Partners Llp | $1.86M | 1.08 | 1.99M | -62.14% | -$3.05M | 0.15 | |
| Jacobs Levy Equity Management | $1.79M | 1.04 | 1.91M | -43.86% | -$1.39M | 0.01 | |
| Assenagon Asset Management S.A. | $1.58M | 0.92 | 1.69M | -31.59% | -$727,711.13 | <0.01 | |
| Marshall Wace | $1.37M | 0.8 | 1.47M | -38.34% | -$850,954.09 | <0.01 | |
| Acuitas Investments, LLC | $1.2M | 0.7 | 1.28M | +40.54% | +$345,093.41 | 0.63 | |
| Charles Schwab | $1.05M | 0.61 | 1.13M | +3.14% | +$32,129.95 | <0.0001 | |
| Alyeska Investment Group L P | $998,914.00 | 0.58 | 1.07M | -69.62% | -$2.29M | 0.01 | |
| Cm Management Llc | $878,005.00 | 0.51 | 939,847 | 0% | +$0 | 0.04 | |
| Ubs Oconnor Llc | $874,056.00 | 0.51 | 935,620 | -25.2% | -$294,386.90 | 0.08 | |
| Almitas Capital LLC | $859,674.00 | 0.5 | 920,225 | New | +$859,674.00 | 0.45 | |
| Goldman Sachs | $663,568.00 | 0.39 | 710,306 | -17.78% | -$143,458.58 | <0.0001 | |
| State Street | $646,304.00 | 0.38 | 691,826 | -3.39% | -$22,701.06 | <0.0001 | |
| Connor Clark & Lunn Investment Management Ltd | $536,277.00 | 0.31 | 574,049 | +15.57% | +$72,240.81 | <0.01 | |
| Barclays | $535,000.00 | 0.31 | 572,975 | +0.89% | +$4,736.78 | <0.0001 | |
| Dimensional Fund Advisors | $507,983.00 | 0.3 | 543,762 | -0.53% | -$2,711.99 | <0.0001 | |
| Schonfeld Group | $500,544.00 | 0.29 | 535,800 | +41.97% | +$147,977.17 | <0.01 | |
| Invesco | $491,710.00 | 0.29 | 526,343 | +73.2% | +$207,805.47 | <0.0001 | |
| AQR Capital | $385,256.00 | 0.24 | 430,983 | -69.98% | -$897,982.24 | <0.01 | |
| Susquehanna International Group | $355,929.00 | 0.21 | 380,999 | +369.13% | +$280,058.94 | <0.0001 | |
| Northern Trust | $335,510.00 | 0.2 | 359,142 | -15.72% | -$62,569.83 | <0.0001 | |
| Balyasny Asset Management Llc | $279,917.00 | 0.16 | 299,633 | -72.76% | -$747,702.45 | <0.01 | |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Am Main | $269,641.00 | 0.16 | 288,634 | 0% | +$0 | <0.0001 | |
| Macquarie Group | $240,000.00 | 0.14 | 256,385 | 0% | +$0 | <0.0001 | |
| Tealwood Asset Management | $217,005.00 | 0.13 | 232,289 | +24.78% | +$43,091.03 | 0.05 | |
| Ameriprise Financial | $206,080.00 | 0.12 | 220,596 | -51.2% | -$216,253.40 | <0.0001 | |
| Public Employees Retirement System Of Ohio | $158,580.00 | 0.09 | 169,749 | -38.26% | -$98,254.79 | <0.01 | |
| Morgan Stanley | $157,694.00 | 0.09 | 168,800 | -69.18% | -$354,015.56 | <0.0001 | |
| Cambridge Investment Research Advisors Inc | $118,000.00 | 0.07 | 126,009 | -3% | -$3,652.12 | <0.0001 | |
| Y Intercept Hong Kong Ltd | $119,170.00 | 0.07 | 127,564 | New | +$119,170.00 | 0.01 | |
| Fidelity Investments | $117,191.00 | 0.07 | 125,445 | -0.96% | -$1,137.86 | <0.0001 | |
| T. Rowe Price | $117,000.00 | 0.07 | 124,750 | 0% | +$0 | <0.0001 | |
| Moloney Securities Asset Management Llc | $98,189.00 | 0.06 | 105,105 | -8.69% | -$9,341.99 | 0.02 |